hotspot -WSS

hotspot

author：focus 2025-09-06 04:41:10 - browse：1

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： New case study details death in closely watched Alzhiemer's trial

WSS

Community addresses injustice for Long Island mothers

These geoengineering technologies could help combat the climate crisis, scientists say

Make 'food is medicine' a key part of White House nutrition meeting

UpToDate has a racism problem: Dr. Stanley Goldfarb

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Pfizer's Covid pill remains 89% effective in final analysis, company says

focus

hotspot

Sign up for D.C. Diagnosis

hotspot

Jerome Adams on the need for new antivirals for Covid

The biotech scorecard for Q3: 15 stock

Wildfire smoke exposes gaps in outdoor worker protections

Fatty liver disease was alleviated by Lilly’s ‘triple

Trump demands the U.S. pay no more for drugs than other countries … again

Skip the lead apron during X

After affirmative action ruling, medical educators look to 'holistic review'

'Screen and refer' systems are hurting patients

Bright Health sells Medicare Advantage business to Molina

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

explore

Dexcom's push to bring CGM to type 2 diabetes patients

RaDonda Vaught case: a double standard for nurses, physicians

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Brain 'hot spot' may explain why African Americans feel greater pain

Pfizer's Covid pill remains 89% effective in final analysis, company says

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

focus

hotspot

explore

focus